This week we've kept Eyes On the MFN and Tariff news, plus the Moderna x HHS Break-up and the Lilly x SiteOne Deal. The BioPharma Marketplace is in flux and we're watching to see how everyone is adapting and re-aligning their strategies.

We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.

This month, we've had Eyes on investment trends, strategic restructuring, and FDA decisions. Fall seems to be gearing up, and we can't wait

Some of this week's news includes Casgevy Approval, Novo's REDEFINE 4 Trial, , new Manufacturing plant and more.

While we've been curating 3Q23 Results reports, we've had eyes on drug approvals, Business Development activities, & even some patent ...

This was a busy week for Healthcare with 1Q22 Results. The PharmaTell Team had eyes on some of the US FDA decisions + Roche's SKYSCRAPER-01